Rebecca J Schmidt1, Daniel L Landry2, Lewis Cohen3, Alvin H Moss1, Cheryl Dalton1, Brian H Nathanson4, Michael J Germain2. 1. Department of Medicine, Sections of Nephrology and Supportive Care, West Virginia University School of Medicine, Morgantown, WV, USA. 2. Division of Nephrology, Baystate Medical Center, University of Massachusetts Medical School-Baystate, Springfield, MA, USA. 3. Department of Psychiatry, Baystate Medical Center, University of Massachusetts Medical School-Baystate, Springfield, MA, USA. 4. OptiStatim, LLC, Longmeadow, MA, USA.
Abstract
BACKGROUND: Guiding patients with advanced chronic kidney disease (CKD) through advance care planning about future treatment obliges an assessment of prognosis. A patient-specific integrated model to predict mortality could inform shared decision-making for patients with CKD. METHODS: Patients with Stages 4 and 5 CKD from Massachusetts (749) and West Virginia (437) were prospectively evaluated for clinical parameters, functional status [Karnofsky Performance Score (KPS)] and their provider's response to the Surprise Question (SQ). A predictive model for 12-month mortality was derived with the Massachusetts cohort and then validated externally on the West Virginia cohort. Logistic regression was used to create the model, and the c-statistic and Hosmer-Lemeshow statistic were used to assess model discrimination and calibration, respectively. RESULTS: In the derivation cohort, the SQ, KPS and age were most predictive of 12-month mortality with odds ratios (ORs) [95% confidence interval (CI)] of 3.29 (1.87-5.78) for a 'No' response to the SQ, 2.09 (95% CI 1.19-3.66) for fair KPS and 1.41 (95% CI 1.15-1.74) per 10-year increase in age. The c-statistic for the 12-month mortality model for the derivation cohort was 0.80 (95% CI 0.75-0.84) and for the validation cohort was 0.74 (95% CI 0.66-0.83). CONCLUSIONS: Our integrated prognostic model for 12-month mortality in patients with advanced CKD had good discrimination and calibration. This model provides prognostic information to aid nephrologists in identifying and counseling advanced CKD patients with poor prognosis who are facing the decision to initiate dialysis or pursue medical management without dialysis.
BACKGROUND: Guiding patients with advanced chronic kidney disease (CKD) through advance care planning about future treatment obliges an assessment of prognosis. A patient-specific integrated model to predict mortality could inform shared decision-making for patients with CKD. METHODS:Patients with Stages 4 and 5 CKD from Massachusetts (749) and West Virginia (437) were prospectively evaluated for clinical parameters, functional status [Karnofsky Performance Score (KPS)] and their provider's response to the Surprise Question (SQ). A predictive model for 12-month mortality was derived with the Massachusetts cohort and then validated externally on the West Virginia cohort. Logistic regression was used to create the model, and the c-statistic and Hosmer-Lemeshow statistic were used to assess model discrimination and calibration, respectively. RESULTS: In the derivation cohort, the SQ, KPS and age were most predictive of 12-month mortality with odds ratios (ORs) [95% confidence interval (CI)] of 3.29 (1.87-5.78) for a 'No' response to the SQ, 2.09 (95% CI 1.19-3.66) for fair KPS and 1.41 (95% CI 1.15-1.74) per 10-year increase in age. The c-statistic for the 12-month mortality model for the derivation cohort was 0.80 (95% CI 0.75-0.84) and for the validation cohort was 0.74 (95% CI 0.66-0.83). CONCLUSIONS: Our integrated prognostic model for 12-month mortality in patients with advanced CKD had good discrimination and calibration. This model provides prognostic information to aid nephrologists in identifying and counseling advanced CKD patients with poor prognosis who are facing the decision to initiate dialysis or pursue medical management without dialysis.
Authors: Sarah J Ramer; Nicolas A Baddour; Edward D Siew; Huzaifah Salat; Aihua Bian; Thomas G Stewart; Susan P Y Wong; Manisha Jhamb; Khaled Abdel-Kader Journal: Am J Nephrol Date: 2020-07-28 Impact factor: 3.754
Authors: Noel Engels; Gretchen N de Graav; Paul van der Nat; Marinus van den Dorpel; Anne M Stiggelbout; Willem Jan Bos Journal: BMJ Open Date: 2022-09-21 Impact factor: 3.006
Authors: Nwamaka D Eneanya; Shananssa G Percy; Taylor L Stallings; Wei Wang; David J R Steele; Michael J Germain; Jane O Schell; Michael K Paasche-Orlow; Angelo E Volandes Journal: Am J Nephrol Date: 2020-08-13 Impact factor: 3.754
Authors: Nwamaka D Eneanya; Joshua R Lakin; Michael K Paasche-Orlow; Charlotta Lindvall; Edward T Moseley; Lori Henault; Amresh D Hanchate; Ernest I Mandel; Susan P Y Wong; Sophia N Zupanc; Aretha Delight Davis; Areej El-Jawahri; Lisa M Quintiliani; Yuchiao Chang; Sushrut S Waikar; Amar D Bansal; Jane O Schell; Andrew L Lundquist; Manjula Kurella Tamura; Margaret K Yu; Mark L Unruh; Christos Argyropoulos; Michael J Germain; Angelo Volandes Journal: BMJ Open Date: 2022-04-08 Impact factor: 2.692
Authors: Taylor L Stallings; Jennifer S Temel; Tamar A Klaiman; Michael K Paasche-Orlow; Margarita Alegria; Ann O'Hare; Nina O'Connor; Laura M Dember; Scott D Halpern; Nwamaka D Eneanya Journal: BMJ Open Date: 2021-02-22 Impact factor: 2.692